It could be a game changer if, as we have just witnessed during this pandemic, the pharmaceutical industry works in a collaborative way to innovate, share research and empower researchers. The approach challenges the strong IP protection system which has been in place for generations due to the impact of Brexit.
Next year UK Pharma companies will have to apply for patient protection in the UK and the EU to protect their IP from next year.